BioMarin Pharmaceutical Inc. (BMRN) Stock AnalysisBMRNBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. Galafold (migalastat) is its oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease. Its portfolio also includes ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $54.68 and the forward P/E ratio of 9.40, BioMarin Pharmaceutical Inc appears to be undervalued compared to its earnings potential. However, the RSI of 33.66 suggests that the stock is oversold, indicating a potential rebound. The main risk is the recent decline in net income, which fell to $44.76 million in Q2 2026 from $105.53 million in Q1 2026, highlighting volatility in earnings. Therefore, while there are positive catalysts such as successful clinical trials, the stock should be monitored closely before making a buy decision.

24 analysts cover BMRN: 19 rate it Buy, 5 Hold and 0 Sell. The average price target is 87.35.